Compare ESCA & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESCA | FENC |
|---|---|---|
| Founded | 1922 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 257.2M | 230.8M |
| IPO Year | 1995 | 2010 |
| Metric | ESCA | FENC |
|---|---|---|
| Price | $18.80 | $10.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 31.4K | ★ 193.6K |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.50% | N/A |
| EPS Growth | ★ 6.45 | N/A |
| EPS | ★ 0.32 | 0.01 |
| Revenue | ★ $180,541,000.00 | $44,642,000.00 |
| Revenue This Year | $4.15 | $65.12 |
| Revenue Next Year | N/A | $41.08 |
| P/E Ratio | ★ $58.41 | $1,015.00 |
| Revenue Growth | ★ 2.71 | N/A |
| 52 Week Low | $11.41 | $5.65 |
| 52 Week High | $21.32 | $11.31 |
| Indicator | ESCA | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 46.37 | 48.70 |
| Support Level | $17.57 | $10.04 |
| Resistance Level | $19.00 | $10.45 |
| Average True Range (ATR) | 0.73 | 0.56 |
| MACD | -0.01 | -0.12 |
| Stochastic Oscillator | 36.78 | 20.07 |
Escalade Inc manufactures and distributes sporting goods for a varied range of activities. These sports include archery, table tennis, basketball goals, trampoline, play systems, fitness, game tables like hockey and soccer, billiards, darting, and other outdoor games. These products are sold under the brand names like Goalrilla, Goalsetter, Woodplay, Silverback, Nodor, Rage, Child Life, among others. The geographic segments in which the company operates are the United States, Canada, Australia, and Other regions.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.